ConfometRx employs a structure-based approach to drug discovery, focusing on G-Protein Coupled Receptors (GPCRs), which are critical targets in the development of novel therapeutics. The company has developed expertise in elucidating the structures of GPCRs in their pharmacologically relevant states, allowing for a deeper understanding of these complex proteins. This knowledge facilitates the advancement of GPCR-targeted drug candidates across various therapeutic areas, including respiratory, central nervous system (CNS), and metabolic diseases. 

The company is actively engaged in the lead optimization and pre-clinical development of multiple small molecule candidates targeting specific GPCRs. Their pipeline includes collaborations with biopharmaceutical partners to enhance the development of these candidates, which address conditions such as Parkinson's disease, psychiatric disorders, and pain management. By leveraging their comprehensive approach to drug discovery, ConfometRx aims to bring innovative treatments to market that target previously challenging GPCRs.

United States

ConfometRx is a leader in G protein coupled receptor (GPCR) structural characterization and analysis and GPCR-targeted drug discovery.

Central Nervous System (CNS)

Metabolic Diseases

Nervous System Diseases

Pathological Conditions

Psychological Diseases

ConfometRx

Metabolic disorder

Partner Program - Target  A (Undisclosed Drug Candidate)

Biologics

California - North

California

Antibodies

Small Molecule Pharmaceuticals

Therapeutic

ConfometRx

Company Details